[Clinical analysis of serum endothelin in type 2 diabetic patients with vascular complications].

OBJECTIVE: To explore the clinical significance of changes in urine microalbumin (UM) and endothelin (ET) in different courses of type 2 diabetes. METHODS: A clinical analyses of 30 type 2 diabetic patients with vascular complications (group A) was conducted in comparison with type 2 diabetic patients without vascular complications (group B) and patients with impaired glucose tolerance (IGT, group C). With 30 healthy subjects with family history of type 2 diabetes (group D) and 30 healthy subjects without such family history (group E) as controls, UM and ET were determined in all the subjects for a statistical analysis. RESULTS: Significant differences in UM content was noted between group A and the other 4 groups (P<0.05), while the content did not differ significantly between the latter 4 groups (P>0.05). ET content was significantly higher in group A than in the other 4 groups (P<0.01), and was the lowest in group E (P<0.01). CONCLUSIONS: Type 2 diabetic patients sustain extensively impaired endothelium function, which is exacerbated with the progression of the disease courses. Synchronized changes between vascular complications and impaired endothelium function indicates that vascular endothelial injury relates to vascular complications and the progression of diabetes.

[Relationship between serum vWF and PAF in type 2 diabetic patients and diabetic nephropathy].

OBJECTIVE: To observe the changes in urine albumin (UALB), von Willebrand factor (vWF) and platelet-activating factor (PAF) in different courses of type 2 diabetes. METHODS: Levels of UALB, vWF and PAF were determined in 30 type 2 diabetic nephropathy patients(group A), type 2 diabetic patients without DNP(group B, n=30), patients with impaired glucose tolerance (group C, n=30), the first-degree relatives of type 2 diabetic patients with normal glucose tolerance(group D, n=30) and 30 normal glucose tolerance subjects without family history of type 2 diabetes(group E). RESULTS: UALB and PAF contents were significantly higher in group A than in the other groups (P<0.01), while between the latter 4 groups, the contents showed no significant differences (P>0.05). Serum vWF level was significantly higher in group A than those in the other groups (P<0.05). CONCLUSIONS: Renal dysfunction and platelet activation are present in type 2 diabetes with microvascular complications, and the synchronized changes between renal dysfunction and platelet activation indicate the involvement of elevated PAF in vascular injury.